From oral solid doses (OSD) and sterile injectables (SI) to complex biologics, Pfizer CentreOne provides premium manufacturing solutions across diverse modalities built on a decades-long legacy of bringing high-quality products to commercialization.

In this conversation with Contract Pharma, Jim Donovan, Vice President of Pfizer CentreOne, highlights the organization’s OSD network, which uses a structure that balances broad thought leadership with specific technical differentiation across sites. He emphasizes how Pfizer CentreOne helps customers navigate complexity in OSD manufacturing and speaks to broader industry themes such as selecting the right manufacturing approach and the importance of aligning network capabilities with long-term commercial goals.

Contract Pharma: What are the key market or scientific forces shaping complexity in today’s OSD development and manufacturing landscape?

Jim Donovan: The complexity in oral solid dose manufacturing today is being driven by both science and supply expectations. On the science side, we’re seeing…